Novelion Therapeutics Inc. (NASDAQ:NVLN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

0
Novelion Therapeutics Inc. (NASDAQ:NVLN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Novelion Therapeutics Inc. (NASDAQ:NVLN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November19, 2018, the Board of Directors and the Compensation Committee of Novelion Therapeutics Inc. (the “Company”), and the independent directors of the Board of Directors of Aegerion Pharmaceuticals,Inc. (the Company’s wholly-owned operating subsidiary), approved a retention plan (the “Key Executive Incentive Plan”) for certain executive officers, including Benjamin Harshbarger, the Company’s Interim Chief Executive Officer and General Counsel, Michael Price, the Company’s Executive Vice President and Chief Financial Officer, and Roger Louis, the Company’s Global Chief Compliance Officer. Under the terms of the Key Executive Incentive Plan, participants will be entitled to a bonus opportunity, payable in three tranches, based on the levels of achievement by the Company of a cumulative net operating cash flow target (the “NOCF”) over the course of two performance periods (which, together, represent 60% of the aggregate payout (the “NOCF Portion”)) and the completion of a transaction (the “Transaction Event” and the date on which the Transaction Event occurs, the “Transaction Date”) in connection with the Company’s review of strategic alternatives (representing 40% of the aggregate payout (the “Transaction Event Portion” and, together with the NOCF Portion, the “Total Target Award”)), as follows:

Tranche

Metric

Payout

MeasurementPeriod

One

NOCF

25% of the NOCF Portion

Earlier of (i)February28, 2019 and (ii)the Transaction Date*

Two

NOCF

75% of the NOCF Portion

March1, 2019 through the Transaction Date**

Three

Transaction Event

50% of the Transaction Event Portion

Transaction Date

* If the Transaction Date occurs first, then achievement of the NOCF metric shall be determined as of the end of the last completed calendar month preceding the Transaction Date.

** If the Transaction Date occurs prior to March1, 2019, the participant shall be eligible to earn the entire NOCF Portion, based on the level of achievement of the NOCF target determined as of the end of the last completed calendar month preceding the Transaction Date.

The NOCF Portion is subject to a minimum level of achievement, at which level the participant would be eligible to receive 50% of the target NOCF Portion, and is capped at a payout of 120% of the target NOCF Portion if the NOCF performance meets or exceeds the maximum performance level (if the minimum level of achievement is not attained, no amounts are payable under the NOCF Portion). If performance is between the minimum and target performance levels or the target and maximum performance levels, then the amount of the NOCF Portion shall be determined by linear interpolation.

The Transaction Event Portion is subject to increase based on an award modifier depending on the type of Transaction Event (if any), and based on the consummation date of such Transaction Event, which modifier would increase the target Transaction Event Portion by a maximum of 25%.

A participant’s right to the Total Target Award will be forfeited upon an employment termination prior to the date on which such award is paid. However, in the event of death or disability, termination by the Company without cause or a resignation by the participant with good reason, in each case prior to the applicable payment date, the amounts payable under the Total Target Award will be prorated for the number of completed months the participant was actively employed during the applicable performance period, and measured based upon actual performance at the end of each Measurement Period. Further, if a participant resigns other than for good reason or is terminated for cause, in each case within 90 days following receipt of any portion of the Total Target Award (the “Clawback Period”), the value of all payouts paid to such participant within the Clawback Period (on an after-tax basis) shall be repaid to the Company.

In connection with the Key Executive Incentive Plan (and, for Mr.Harshbarger, also in recognition of his previously disclosed appointment as Interim Chief Executive Officer), Mr.Harshbarger and Mr.Price (a)received salary increases such that their annual base salaries shall be $480,000 and $440,000 (effective December 1, 2018), respectively, and (b)are eligible for a Total Target Award of $840,000 and $440,000, respectively. Mr.Louis is eligible for a Total Target Award of $288,400.


About Novelion Therapeutics Inc. (NASDAQ:NVLN)

Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company’s portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.